1. Search Result
Search Result
Pathways Recommended: MAPK/ERK Pathway
Results for "

pathways

" in MedChemExpress (MCE) Product Catalog:

2374

Inhibitors & Agonists

67

Screening Libraries

10

Fluorescent Dye

35

Biochemical Assay Reagents

127

Peptides

1

MCE Kits

34

Inhibitory Antibodies

751

Natural
Products

144

Isotope-Labeled Compounds

5

Click Chemistry

21

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W089835
    Sodium taurodeoxycholate hydrate
    2 Publications Verification

    G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Metabolic Disease
    Sodium taurodeoxycholate hydrate, a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Sodium taurodeoxycholate hydrate activates the S1PR2 pathway in addition to the TGR5 pathway .
    Sodium taurodeoxycholate hydrate
  • HY-B1899A
    Taurodeoxycholic acid sodium hydrate
    2 Publications Verification

    Sodium taurodeoxycholate monohydrate

    G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Metabolic Disease
    Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Taurodeoxycholic acid sodium hydrate activates the S1PR2 pathway in addition to the TGR5 pathway .
    Taurodeoxycholic acid sodium hydrate
  • HY-P99965

    SKY59; RO7112689

    Complement System Cardiovascular Disease Metabolic Disease
    Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
    Crovalimab
  • HY-Y0641

    m-Phenoxybenzaldehyde

    Complement System Inflammation/Immunology
    3-Phenoxybenzaldehyde has weak complement classical pathway inhibition and hemolytic activity .
    3-Phenoxybenzaldehyde
  • HY-N9474

    5-Diphosphomevalonic acid tetralithium; Mevalonic acid 5-diphosphate tetralithium

    Endogenous Metabolite Others
    Mevalonic acid 5-pyrophosphate (5-Diphosphomevalonic acid) tetralithium is an endogenous metabolite of the mevalonate pathway .
    Mevalonic acid 5-pyrophosphate tetralithium
  • HY-12848C
    SAG dihydrochloride
    20+ Cited Publications

    Smo Cancer
    SAG dihydrochloride is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG dihydrochloride activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
    SAG dihydrochloride
  • HY-129426

    Akt Cancer
    PDK1/Akt/Flt dual pathway inhibitor is one of a component of KP372-1 (HY-15673 ), and inhibits PDK1/Akt/Flt dual pathway .
    PDK1/Akt/Flt dual pathway inhibitor
  • HY-W089835R

    G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Metabolic Disease
    Sodium taurodeoxycholate hydrate (Standard) is the analytical standard of Sodium taurodeoxycholate hydrate. This product is intended for research and analytical applications. Sodium taurodeoxycholate hydrate, a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Sodium taurodeoxycholate hydrate activates the S1PR2 pathway in addition to the TGR5 pathway .
    Sodium taurodeoxycholate hydrate (Standard)
  • HY-N1930

    Hinesol

    Apoptosis Cancer
    (-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer .
    (-)-Hinesol
  • HY-W777433

    Endogenous Metabolite Infection Others
    Cyclobenzaprine b-D-glucuronide is a metabolite of Cyclobenzaprine. Cyclobenzaprine b-D-glucuronide can be used to treat diseases associated with coronavirus infection. Cyclobenzaprine b-D-glucuronide can be used to study the metabolic pathways of Cyclobenzaprine in the body and as a potential candidate for studying coronavirus treatment .
    Cyclobenzaprine b-D-glucuronide
  • HY-W097899
    Vanillylamine
    1 Publications Verification

    Others Others
    Vanillylamine is a derivative of vanillin is synthesized through a transaminase reaction in the phenylpropanoid pathway of capsaicinoid synthesis .
    Vanillylamine
  • HY-155646

    NF-κB Inflammation/Immunology
    Anti-inflammatory agent 48 is an anti-inflammatory agent based on its role in inhibiting the NF-κB signaling pathway and activating HO-1 expression .
    Anti-inflammatory agent 48
  • HY-153456

    Hedgehog Cancer
    Hedgehog IN-2 (Compound 20) is an inhibitor of Hedgehog pathway with an IC50 value less than 0.003 μM in C3H10T1/2 cells .
    Hedgehog IN-2
  • HY-147789

    Akt Neurological Disease Cancer
    FPDT is an anti-glioblastoma agent. FPDT displays the IC50 value of 45–68 μM for GBM cells and >100 μM for astrocytes. Anti-glioblastoma activity of FPDT is linked to downregulation of the AKT pathway .
    FPDT
  • HY-15398C

    Epicholecalciferol

    Hedgehog Cancer
    3-epi-Vitamin D3 (Epicholecalciferol) (Compound 4), a Vitamin D3 analogue, is a Hedgehog pathway inhibitor with an IC50 of 39.2 μM measured in U87MG cells .
    3-epi-Vitamin D3
  • HY-19542
    C6 Ceramide
    2 Publications Verification

    C6-Cer; N-Hexanoylsphingosine

    Apoptosis Cancer
    C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .
    C6 Ceramide
  • HY-P990025

    ARGX-117

    Complement System Inflammation/Immunology
    Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .
    Empasiprubart
  • HY-135282

    Dihydroorotate Dehydrogenase DNA/RNA Synthesis Infection
    DHODH-IN-1 (compound 18d) is a potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC50 of 25 nM. DHODH-IN-1 is an inhibitor of pyrimidine biosynthesis pathway .
    DHODH-IN-1
  • HY-156814

    Hedgehog Cancer
    HPP-9 is a Proteolysis-Targeting Chimeras (PROTACs) based on Hedgehog Pathway Inhibitor-1 (HPI-1), with the pIC50 of 6.71, that can degrade BET bromodomains. HPP-9 has antitumor activity [1[.
    HPP-9
  • HY-W738465

    N-Carbonylguanidine

    Endogenous Metabolite Metabolic Disease
    N,N-Dimethylamidino Urea (N-Carbonylguanidine) is an intermediate in the electrochemical oxidation of Metformin (HY-B0627). Metformin can be used in the study of type 2 diabetes. N,N-Dimethylamidino Urea can be used as a marker to study the metabolic pathway of metformin in vivo .
    N,N-Dimethylamidino Urea
  • HY-W011474

    NF-κB Inflammation/Immunology
    Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model .
    Geranylgeraniol
  • HY-169126

    β-catenin Wnt Cancer
    β-catenin modulator IIa-661 is a β-catenin modulator that modulates β-catenin activity and inhibits the activity of the Wnt/wingless (wg) signaling pathway. β-catenin modulator IIa-661 can be utilized in cancer research .
    β-catenin modulator IIa-661
  • HY-117229

    Drug Metabolite Cancer
    Sonidegib metabolite M48 is the main circulating metabolite of Sonidegib. Sonidegib is a hedgehog pathway inhibitor. M48 showed a much longer Tmax (60 h) than Sonidegib .
    Sonidegib metabolite M48
  • HY-146757

    RIP kinase Inflammation/Immunology
    RIPK1-IN-13 (Compound 8) is a potent inhibitor of RIPK1 with an IC50 value of 1139 nM. RIPK1-IN-13 blocks the activation of the necroptosis pathway via the inhibition of RIPK1. RIPK1-IN-13 has the potential for the research of inflammation diseases .
    RIPK1-IN-13
  • HY-164145

    TGF-β Receptor Others Cancer
    CDD-1653 is a potent and selective BMPR2 inhibitor (IC50=2.8 nM). CDD-1653 reduces the ability of ATP to bind to the kinase domain of BMPR2, thereby affecting the phosphorylation of SMAD1/5/8 transcription factors, which play a key role in the BMP signaling pathway. CDD-1653 can be used to study diseases related to the BMP signaling pathway .
    CDD-1653
  • HY-N0247

    Smo Cancer
    Saikosaponin B1 is a bioactive constituent of Radix Bupleuri with anticancer activity. Saikosaponin B1 significantly inhibits tumor growth in Medulloblastoma (MB) model by inhibiting the Hedgehog pathway through targeting SMO .
    Saikosaponin B1
  • HY-108516

    PARP Cancer
    TC-E 5001 is an inhibitor of Wnt pathway that inhibits tankyrase 1/2 (TNKS1/2) via novel adenosine pocket binding, with Kds of 79 nM and 28 nM, respectively. TC-E 5001 also inhibits Axin2 and STF, with IC50s of 0.709 μM and 0.215 μM, respectively .
    TC-E 5001
  • HY-147897

    Apoptosis Cancer
    Apoptosis inducer 9 induces apoptosis with IC50 value of 4.21 μM. Apoptosis inducer 9 induces apoptosis through the mitochondrial pathway and enhance the expression of Cl-caspase-3, Cl-caspase-9 and Cl-PARP. Apoptosis inducer 9 can be used the potential to develop new anti-proliferative agents .
    Apoptosis inducer 9
  • HY-144841A

    (Rac)-CFT7455

    Molecular Glues Cancer
    (Rac)-Cemsidomide ((Rac)-CFT7455) is the racemate of Cemsidomide (HY-144841) with antitumor activity . Cemsidomide is a ubiquitin ligase pathway Ikaros/Aiolos degrader with molecular glue activity. Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells.
    (Rac)-Cemsidomide
  • HY-157570

    PROTACs STING Infection
    Anti-inflammatory agent 70 (N-Me-SP23) is a STING protein PROTAC degrader and inhibits the STING signaling pathway. Anti-inflammatory agent 70 has anti-inflammatory activity. (Pink: STING inhibitor (HY-47709); Black: linker (HY-W008296); Blue: CRBN Ligand (HY-W460193)) .
    Anti-inflammatory agent 70
  • HY-19542S1

    C6-Cer-d11; N-Hexanoylsphingosine-d11

    Apoptosis Isotope-Labeled Compounds Cancer
    C6 Ceramide-d11 is deuterated labeled C6 Ceramide (HY-19542). C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .
    C6 Ceramide-d11
  • HY-131542

    Aldose Reductase Apoptosis Metabolic Disease
    APPA is an aldose reductase inhibitor. APPA can effectively prevent apoptosis and the symptoms of Streptozotocin (HY-13753)-induced diabetes by inhibiting the polyol pathway in rats. APPA has the potential for diabetic nephropathy (DN) research .
    APPA
  • HY-W011474R

    NF-κB Inflammation/Immunology
    Geranylgeraniol (Standard) is the analytical standard of Geranylgeraniol. This product is intended for research and analytical applications. Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model [4].
    Geranylgeraniol (Standard)
  • HY-13418
    Dorsomorphin dihydrochloride
    Maximum Cited Publications
    520 Publications Verification

    Compound C dihydrochloride; BML-275 dihydrochloride

    Organoid AMPK TGF-β Receptor Autophagy Cancer
    Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
    Dorsomorphin dihydrochloride
  • HY-N0560
    Oroxylin A
    5+ Cited Publications

    Baicalein 6-methyl ether; 6-Methoxybaicalein

    HIF/HIF Prolyl-Hydroxylase Autophagy Virus Protease Cancer
    Oroxylin A is an active flavonoid compound with strong anti-cancer effects. Oroxylin A inhibits the IL-6/STAT3 pathway and NF-κB signaling, inhibits cell proliferation and induces apoptosis. Oroxylin A inhibits colitis-related carcinogenesis .
    Oroxylin A
  • HY-163461

    PARP Cancer
    4F-DDC is a novel PARP1 inhibitor with an IC50 value of 82 nM. 4F-DDC induces DNA damage and activates the cGAS–STING pathway. 4F-DDC inhibits the growth of HCC-1937-derived tumor xenografts .
    4F-DDC
  • HY-N9802

    Apoptosis Bcl-2 Family Cancer
    n-Butyl-β-D-fructofuranoside could be isolated from kangaisan. n-Butyl-β-D-fructofuranoside induces apoptosis through the mitochondrial pathway. n-Butyl-β-D-fructofuranoside can be used for cancer research .
    n-Butyl-β-D-fructofuranoside
  • HY-113071

    MVA

    Endogenous Metabolite Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Mevalonic acid (MVA) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .
    Mevalonic acid
  • HY-128749A

    Calcium D-glucarate tetrahydrate

    Endogenous Metabolite Cancer
    D-Glucaric acid tetrahydrate is the end-products of the D-glucuronic acid pathway in mammals. D-Glucaric acid tetrahydrate is also found in fruits and vegetables. D-Glucaric acid tetrahydrate can be used to reduce cholesterol and inhibits tumor development. D-Glucaric acid tetrahydrate also enhances human immunity and reduce cancer risks .
    D-Glucaric acid tetrahydrate
  • HY-18287A

    Smo Cancer
    MRT-83 (hydrochloride) is the potent antagonist of Smoothened (Smo) receptor. MRT-83 (hydrochloride) inhibits the Hedgehog (Hh) signaling pathway and BODIPY-cyclopamine binding to human Smo. MRT-83 (hydrochloride) has the potential for researching cancer disease .
    MRT-83 hydrochloride
  • HY-119663

    Fungal Infection
    Averantin is the minor metabolite of the fungus Cercospora arachidicola . Averantin is an aflatoxin B1 precursor that can be used in the biosynthetic pathway .
    Averantin
  • HY-114295

    Geranyl pyrophosphate

    Endogenous Metabolite Metabolic Disease
    Geranyl diphosphate is a key intermediate in the isoprenoid biosynthesis pathway (IBP). HY-114295 plays key roles in cellular metabolism and is responsible for the production of both sterol and non-sterol isoprenoids .
    Geranyl diphosphate
  • HY-162867

    Ferroptosis Cancer
    Photosensitizer-5 is a photosensitizer. Photosensitizer-5 has cytotoxicity against HeLa and HepG2 cells, with IC50 values of 10.4 nM and 6.9 nM, respectively. Photosensitizer-5 can lead to lipid peroxidation and induces cell death through an iron-independent ferroptosis-like pathway. Photosensitizer-5 shows anti-tumor activity in HeLa tumor-bearing mice .
    Photosensitizer-5
  • HY-114295A

    Geranyl pyrophosphate triammonium

    Endogenous Metabolite Metabolic Disease
    Geranyl diphosphate triammonium is a key intermediate in the isoprenoid biosynthesis pathway (IBP). Geranyl diphosphate triammonium plays key roles in cellular metabolism and is responsible for the production of both sterol and non-sterol isoprenoids .
    Geranyl diphosphate triammonium
  • HY-113071A
    Mevalonic acid lithium salt
    5+ Cited Publications

    MVA lithium salt

    Endogenous Metabolite Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .
    Mevalonic acid lithium salt
  • HY-116532

    Bcl-2 Family Cancer
    YCW-E11 is a Bcl-2, and Mcl-1 inhibitor with Ki values of 0.83 and 0.33 μM, respectively. YCW-E11 induces cell apoptosis through the mitochondrial pathway and exhibits antitumor activity. YCW-E11 can be utilized in cancer research .
    YCW-E11
  • HY-151934

    Apoptosis Cancer
    ERK-IN-6 (compound 6g) is an potent anti-proliferation agent against esophageal squamous cell carcinoma (ESCC). ERK-IN-6 induces cell apoptosis via ERK pathway. ERK-IN-6 can be used for the research of ESCC .
    ERK-IN-6
  • HY-14664DS

    (3S,5R)-XU 62-320-d6 free acid

    Autophagy Cardiovascular Disease Cancer
    (3S,5R)-Fluvastatin-d6 is the deuterium labeled (3S,5R)-Fluvastatin sodium. Fluvastatin is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1].
    (3S,5R)-Fluvastatin-d6
  • HY-13459

    Smo Cancer
    PF-5274857 is a potent, selective, orally active and brain-penetrant antagonist of Smo, with an IC50 of 5.8 nM and Ki of 4.6 nM. PF-5274857 has potential for research of tumor types including brain tumors and brain metastasis driven by an activated Hh pathway .
    PF-5274857
  • HY-13459A

    Smo Cancer
    PF-5274857 hydrochloride is a potent, selective, orally active and brain-penetrant antagonist of Smo, with an IC50 of 5.8 nM and Ki of 4.6 nM. PF-5274857 hydrochloride has potential for research of tumor types including brain tumors and brain metastasis driven by an activated Hh pathway .
    PF-5274857 hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: